The content in this section is written by a patient advocate, not a medical professional. It is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making medical decisions.
Plain-language guides on clinical trials, plus condition guides that map a diagnosis to recruiting studies.
How Hodgkin vs non-Hodgkin subtype, biopsy markers, and prior treatment change which lymphoma trials may fit.
How stage, MSI/dMMR, KRAS, NRAS, BRAF, HER2, and prior treatment change which colorectal cancer trials may fit.
How POTS, fatigue with PEM, and cognitive symptoms change which Long COVID trials may fit.
How stage, BRAF status, and prior treatment change which melanoma trials may fit.
How disease stage and biomarkers such as amyloid and tau change which Alzheimer's trials may fit.
Leukemia is not one disease. How FLT3, IDH, and NPM1 mutations change which AML trials may fit.
How seizure type, drug resistance, and treatment approach change which epilepsy trials may fit.
How tumor type, grade, and biomarkers such as IDH and MGMT change which trials may fit.
How subtype and biomarkers such as HER2, BRCA, and PIK3CA change which trials may fit.
How resectability and biomarkers such as KRAS, BRCA, and MSI change which trials may fit.
How type and biomarkers such as EGFR, ALK, and KRAS change which trials may fit.
Four ESMO 2026 results in lung cancer and melanoma with steps you can take now, from biomarker testing to open clinical trials.
Osimertinib (Tagrisso) for uncommon EGFR mutations such as G719X, S768I, L861Q, and exon 20 insertions: what the evidence covers, plus active clinical trials.
Mental health clinical trials may test medication, therapy, or devices. How they differ from cancer trials, and how to start looking.
Learn what screening and informed consent involve before you join a clinical trial, which questions to ask, and which red flags mean you should walk away.